Madrigal Swings To Q3 Profit As Rezdiffra Sales Jump 50%
Madrigal Pharmaceuticals (MDGL) reported a Q3 profit of $55.44M, reversing a year-earlier loss, driven by a 50% sales increase of Rezdiffra to $431.30M. R&D expenses declined, while SG&A and cost of sales rose. Over 55,850 patients are now using Rezdiffra, and the company plans a Phase 3 trial for MASH cirrhosis in 2027. MDGL stock is up 9.89%.
How this was made
The 30-second read
Why it matters
The earnings beat provides fresh, material information that can influence trading decisions on MDGL and related biotech names.
Market read
The earnings surprise is likely to drive short‑term buying interest in MDGL and may have spillover effects on the broader biotech sector.
What to watch
Upcoming Phase 3 trials and royalty payments to Roche could affect future cash flow.
Background
Madrigal Pharmaceuticals announced its Q3 FY26 results, highlighting a profit turnaround and a 50% jump in Rezdiffra sales.
Ticker impact
MDGL reported Q3 FY26 profit of $55.44M, a swing from a $114.19M loss a year earlier, with 50% revenue growth driven by Rezdiffra sales.
upward pressure as the market prices in the profit turnaround and higher sales guidance.
The surprise profit and strong revenue growth are fresh, material data that can move the share price in the near term.
Market effects
Positive earnings may lift other biotech firms focused on liver disease therapies.
U.S. biotech sector gains modestly on the news.
Limited to investors tracking US‑listed biotech stocks.
Counterpoint
If the profit swing is viewed as a one‑time accounting effect, the rally could be muted.
Key entities
- companyMadrigal Pharmaceuticals, Inc.
US‑listed biotech company developing the liver‑targeted drug Rezdiffra.
